At a median follow-up of 4.4 years (IQR 4–4.8 years), seven patients experienced a distant recurrence of the HER2 + BC (one of them also experienced a locoregional recurrence), and two of them died of HER2 + BC. This evidence concerns the gene ERBB2 and breast cancer.